Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion description "[Use of selective COX-2 inhibitors resulted in a significant risk reduction for each type of cancer (71% for breast cancer, 55% for prostate cancer, 70% for colon cancer, and 79% for lung cancer) and an overall 68% risk reduction for all four cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion evidence source_evidence_literature NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion SIO_000772 17612052 NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion wasDerivedFrom befree-2016 NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion wasGeneratedBy ECO_0000203 NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- befree-2016 importedOn "2016-02-19" NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.